Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under ADIAL PHARMACEUTICALS, INC. in our court records and SEC 8-K records (as of 2026-10-18).
- Leadership changes: the latest reported is Tony Goodman (Form 8-K filed 2026-06-11). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Coastlands Capital LP (filed 2026-07-01).
Who is behind it
Adial Pharmaceuticals, Inc.: incorporated in Delaware; business address in Charlottesville, Virginia; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-07-01).
Officers and directors, each with the role and the filing that names them:
- Cary J. Claiborne: Executive Officer, Director (Form D, 2025-12-03)
- Vinay Shah: Executive Officer (Form D, 2025-12-03)
- James K. Anderson: Director (Form D, 2025-12-03)
- Robertson H. Gilliland: Director (Form D, 2025-12-03)
- James W. Newman, Jr.: Director (Form D, 2025-12-03)
- Kevin W. Schuyler, CFA: Director (Form D, 2025-12-03)
- Tony Goodman: Executive Officer, Director (Form D, 2025-12-03)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-07-01 | Coastlands Capital LP | 14.22% |
| Schedule 13G, 2026-06-24 | Coastlands Capital LP | 9.98% |
| Schedule 13G/A, 2026-05-15 | Armistice Capital, LLC | 4.99% |
| Schedule 13G, 2026-02-18 | Armistice Capital, LLC | 9.99% |
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-06-11 | Tony Goodman | departed | ||
| Form 8-K, 2026-06-11 | Matt Davidson | Chief Development Officer | appointed |
Money raised
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2025-12-03 | $4.29M | $4.29M |
| Form D, 2025-05-14 | $4.82M | $4.82M |
| Form D, 2024-03-14 | $288K | $288K |
| Form D, 2023-10-26 | $4M | $4M |
| Form D, 2023-06-05 | $53K | $3.05M |
| Form D, 2023-03-06 | $62K | $62K |
Latest IPO step: Adial Pharmaceuticals, Inc. amended its IPO registration (S-1/A, 2025-06-13).
IPO filings: S-1/A, 2025-06-13, S-1, 2025-06-06, S-1, 2024-12-20; ticker ADIL on Nasdaq Capital Market.
Acquisitions reported on Form 8-K, Item 2.01: acquired Azora Therapeutics, Inc. (2026-06-11).
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
Permanent URL:
https://mentionfox.com/who-owns/adial-pharmaceuticalsLast updated 2026-10-18
Primary record: Schedule 13G/A, 2026-07-01 · Form D, 2025-12-03 · Form 8-K, 2026-06-11 · S-1/A, 2025-06-13
Who owns Adial Pharmaceuticals, Inc.? Owners, funding and legal record. MentionFox, 2026-10-18. https://mentionfox.com/who-owns/adial-pharmaceuticals